On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...
Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...
As China's biotech sector continues to buzz with innovation, the country is rapidly integrating into the global clinical ...
AstraZeneca’s Saphnelo (SC) administration has shown a decrease in disease activity in individuals with systemic lupus ...
Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of trial processes.
PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing correction in a Phase I trial.
Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.
Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033. Image credit: Antonio Marca / Shutterstock.com Eli Lilly ...
The main concerns about tariffs that businesses have are higher input costs and uncertainty in long-term planning.
ACL Digital will also be able to drive digital transformation for biotech, pharmaceutical and medical device companies. Credit: tilialucida / Shutterstock.com. ACL Digital has acquired US-based ...
In the head-to-head trial, Lilly’s oral drug emerged on top, outperforming Novo Nordisk’s semaglutide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback